ReviewIntegrative medicine research2021
Challenges and strategies for implementing Chinese medicine during COVID-19 in Malaysia.
Review in Integrative medicine research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Herbal medicine for COVID-19: An overview of systematic reviews and meta-analysis.Phytomedicine : international journal of phytotherapy and phytopharmacology · 2022Pooled it
- Topic and Trend Analysis of Weibo Discussions About COVID-19 Medications Before and After China's Exit from the Zero-COVID Policy: Retrospective Infoveillance Study.Journal of medical Internet research · 2023Article
- The Efficacy of Herbs as Complementary and Alternative Therapy in Recovery and Clinical Outcome Among People with COVID-19: A Systematic Review, Meta-Analysis, and Meta-Regression.Therapeutics and clinical risk management · 2023Review
- An umbrella review of Lianhua Qingwen combined with Western medicine for the treatment of coronavirus disease 2019.Acupuncture and herbal medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImplementing Chinese medicine (CM) for COVID-19 in Malaysia is challenging for local CM practitioners. The successful experience of CM in China can only be partially adopted in Malaysia due to differences in the national health care system and legislation, geographical health disparities and cultural diversity. Despite all the challenges, Malaysian CM practitioners have managed to thrive and found a Malaysian CM solution amid COVID-19.
methodsA literature review was conducted using various databases and gray literature from inception to August 15, 2021, to evaluate the challenges faced by Malaysian CM practitioners and the corresponding strategies in Malaysia's country context during COVID-19.
resultsA total of 9 challenges and issues faced by Malaysian CM practitioners during COVID-19 were identified. Their corresponding strategies were further categorized into 3 phases, namely, preparation, development and implementation. The strategies were appraised using the SWOT analysis method, and 17 factors were identified. Strength analysis includes personalized CM prescriptions with online consultations in Malaysia. Limited research input for CM in COVID-19 and the inadequate research capacity of local CM institutions are discussed in threat analysis.
conclusionVarious approaches have been implemented by Malaysian CM practitioners to provide safe, qualified and effective CM services for COVID-19 at the community level, aiming to reduce the national health care burden. A public-private partnership initiative can bridge the knowledge gap and optimize the role of CM in the health emergency system. This Malaysian CM solution can provide insights to interested countries to capitalize on the potential contribution of Traditional and Complementary Medicine (T&CM) in the era of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.